By Ann Palma —

About
Court Report Supplement:  Periodically, we will
report on biotech and pharma cases that were inadvertently omitted from
our Court Report column.

TriPharma,
LLC v. First Fruits Business Ministry LLC et al.
8:12-cv-404;
filed March 14, 2012 in the Central District of California

• Plaintiff: 
TriPharma, LLC
• Defendants: 
First Fruits Business Ministry LLC; First Fruits Beverage Co., LLC; Roger
J. Catarino

Numerous
counts related to the Plaintiff's Exclusive Marketing Agreement directed to U.S.
Patent No. 6,800,892 ("Methods to Reduce Body Fat," issued May 31,
2005), which covers methods and compositions for reducing the percentage of
body fat in a mammal and the level of leptin in the bloodstream of a mammal,
based on the Defendants' market and sale of products covered by the '892
patent, including TrimFit.  View the complaint here.

Lycored Corp. et al. v. U.S. Nutraceuticals
LLC et al.
2:2012-cv-01695;
filed March 19, 2012 in the District of New Jersey

• Plaintiffs: 
Lycored Corp.; Lycored Ltd.
• Defendants: 
U.S. Nutraceuticals LLC (d/b/a Valensa International); E.I.D. Parry (India)
Ltd.; Parry Phytoremedies Pvt. Ltd.

Infringement
of U.S. Patent Nos. 6,515,018 ("Synergistic Compositions for Lycopene and
Vitamin E for the Prevention of LDL Oxidation," issued February 4, 2003),
5,837,311 ("Industrial Processing of Tomatoes and Product Thereof,"
issued November 17, 1998), and 5,965,183 ("Stable Lycopene Concentrates
and Process for Their Preparation," October 12, 1999) based on Defendants'
manufacture, use, offers for sale, sale, and importation of tomato lycopene products,
including tomato lycopene beadlets, tomato lycopene oil, and tomato lycopene
cold water dispersible powder. View the complaint here.

Trustees of
Columbia University in the City of New York v. Illumina, Inc.
1:12-cv-00376;
filed March 26, 2012 in the District of Delaware

Infringement
of U.S. Patent Nos. 7,635,578 ("Massive Parallel Method for Decoding DNA
and RNA," issued December 22, 2009), 7,713,698 ("Massive Parallel
Method for Decoding DNA and RNA," issued May 11, 2010), 7,790,869 ("Massive Parallel
Method for Decoding DNA and RNA," issued September 7, 2010), 7,883,869 ("Four-Color
DNA Sequencing by Synthesis Using Cleavable Fluorescent Nucleotide Reversible
Terminators," issued February 8, 2011), and 8,088,575 ("Massive
Parallel Method for Decoding DNA and RNA," issued January 3, 2012), based
on Illumina's manufacture, use, offer for sale, sale, and importation of
next-generation-sequencing ("NGS") products that use NGS
technologies, including NGS instruments (HiSeq 2500/1500, Hi Seq 2000/1000,
Genome Analyzer Ilx, MiSeq Personal Sequencer, and HiScanSQ products), kits and
reagents (TruSeq SBS Kit v3-HS, TruSeq SBS Kit v5-GA, and MiSeq Reagent Kit
products), and services (Illumina Genome Network, Illumina Certified Service
Provider (CSPro) Program, and the Individual Genome Sequencing (IGS) services).  View the complaint here.

PerkinElmer
Health Sciences, Inc. v. Agilent Technologies, Inc.
1:12-cv-10562;
filed March 28, 2012 in the District of Massachusetts

Infringement
of U.S. Patent Nos. 5,686,726 ("Composition of Matter of a Population of Multiply Charged Ions
Derived from Polyatomic Parent Molecular Species," issued November 11,
1997) and 5,581,080 ("A Method for Determining Molecular Weight Using
Multiply Charged Ions," issued December 3, 1996) based on Agilent's
manufacture, use, sale, offers for sale, and/or importation of mass
spectrometers and electrospray ion sources, including Agilent's 6100 Series
Quadrupole, 6200 Series TOF, 6300 Series Ion Trap, 6400 Series Triple Quad and
6500 Series Q-TOF models.  View the complaint here.

William M. Yarbrough
Foundation et al. v. Frank Turrentine et al.
1:2012-cv-318;
filed March 30, 2012 in the Western District of Michigan

• Plaintiffs:  The William M. Yarbrough
Foundation; Zanfel Laboratories, Inc.
• Defendants: 
Frank Turrentine; Phoenix Industries, Inc.

Infringement
of U.S. Patent Nos. 7,008,963 ("Urushiol Induced Contact Dermatitis
Solution," issued March 7, 2006) and 6,423,746 ("Urushiol Induced Contact
Dermatitis and Method of Use," issued July 23, 2002) based on the Defendants'
manufacture, use, offers for sale, and/or sale of products indicated for the
treatment of poison ivy, oak, and sumac with an aqueous topical
composition.  View the complaint here.

Gevo, Inc. v.
Butamax™ Advanced Biofuels LLC et al.
1:12-cv-448;
filed April 10, 2012 in the District Court of Delaware

• Plaintiff: 
Gevo, Inc.
• Defendants: 
Butamax™ Advanced Biofuels; E.I. DuPont de Nemours and Co.

Infringement
of U.S. Patent No. 8,153,415 ("Reduced By-Product Accumulation for
Improved Production of Isobutanol," issued April 10, 2012) based on the
Defendants' manufacture of recombinant isobutanol-producing microorganisms.
View the complaint here.